
Opinion|Videos|April 18, 2025
The Role of Continuing Cemiplimab in Second-Line Therapy After Progression
Author(s)Eric K. Singhi, M.D., Ben Creelan, M.D.
Panelists discuss how, cemiplimab, a PD-1 inhibitor, has shown promise as a second-line therapy for advanced NSCLC after progression on prior treatments. Continuing cemiplimab post-progression can enhance survival outcomes by maintaining immune system activation against cancer cells.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Discuss the role of continuing cemiplimab in second-line therapy after progression.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Trade group for transparent PBMs has changed its name
2
Health insurance without a net(work)
3
Some employers steer workers toward cash platforms for GLP-1 obesity drugs
4
Make lab monitoring of patients taking isotretinoin less routine, more based on symptoms
5






























